Perioperative Urinary Excretion of Aquaporin-2 Dependent Upon Vasopressin in Cardiac Surgery

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2019 Nov 9

PMID 31701228

Authors

Masahiro Fujii

Ryosuke Amitani

Ryuzo Bessho

Affiliations

Soon will be listed here.

Abstract

Aquaporin-2 is found in the apical cell membranes of the principal cells of the collecting duct of the kidney. Plasma arginine vasopressin has been reported to be markedly elevated during cardiac surgery. However fluctuations in urine aquaporin-2 levels have never been reported. We aimed to determine the responses of urine aquaporin-2 and evaluated the relationship between urine aquaporin-2 and plasma arginine vasopressin levels during perioperative periods in cardiac surgical patients. Eight patients undergoing elective isolated aortic valve replacement in normothermia were enrolled prospectively. Blood and urine samples were collected preoperatively and on postoperative days 1, 4, and 7. Patients received furosemide and spironolactone, as needed, during the clinical course; tolvaptan was not needed. Median plasma arginine vasopressin levels [with interquartile range] significantly increased to 1.5 [1.3-2.0], 15.3 [11.4-22.2]*, 2.2 [2.1-2.3], 1.7 [1.5-1.9] pg/mL preoperatively, on postoperative days 1, 4, and 7, respectively (*: p = 0.0001). Similarly, levels of urine aquaporin-2 markedly increased in 3.4 [1.9-5.6], 25.8 [18.4-33.5]**, 9.3 [5.9-14.0], 5.4 [5.3-6.1] (ng/mL), respectively (**p = 0.0004). A significant correlation between plasma arginine vasopressin and urine aquaporin-2 was observed during the entire investigation (R = 0.616, p < 0.0001). Plasma arginine vasopressin and urine aquaporin-2 levels were significantly elevated on postoperative day 1 in patients who underwent aortic valve replacement with cardiopulmonary bypass. A significant correlation between plasma arginine vasopressin and urine aquaporin-2 was observed. Urine aquaporin-2 should be further investigated as a potential biomarker for postoperative cardiac dysfunction.

References

Lehot J, Villard J, Piriz H, Philbin D, Carry P, Gauquelin G . Hemodynamic and hormonal responses to hypothermic and normothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1992; 6(2):132-9. DOI: 10.1016/1053-0770(92)90186-b. View

Butler J, Rocker G, Westaby S . Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993; 55(2):552-9. DOI: 10.1016/0003-4975(93)91048-r. View

Levine F, Philbin D, Kono K, Coggins C, Emerson C, Austen W . Plasma vasopressin levels and urinary sodium excretion during cardiopulmonary bypass with and without pulsatile flow. Ann Thorac Surg. 1981; 32(1):63-7. DOI: 10.1016/s0003-4975(10)61376-8. View

Xu D, Martin P, Ohara M, John J, Pattison T, Meng X . Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest. 1997; 99(7):1500-5. PMC: 507969. DOI: 10.1172/JCI119312. View

Marumoto K, Hamada M, Hiwada K . Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond). 1995; 88(5):551-6. DOI: 10.1042/cs0880551. View

Bellos I, Iliopoulos D, Perrea D . The Role of Tolvaptan Administration After Cardiac Surgery: A Meta-Analysis. J Cardiothorac Vasc Anesth. 2019; 33(8):2170-2179. DOI: 10.1053/j.jvca.2018.12.001. View

Kato T, Ono S, Kajimoto K, Kuwaki K, Yamamoto T, Amano A . Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound. J Cardiothorac Surg. 2015; 10:143. PMC: 4631092. DOI: 10.1186/s13019-015-0372-0. View

Ishikawa S, Sasaki S, Nakamura T, Rokkaku K, Kawakami A, Honda K . Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus. J Clin Endocrinol Metab. 1997; 82(6):1823-7. DOI: 10.1210/jcem.82.6.3984. View

Morrison W, Simone S, Conway D, Tumulty J, Johnson C, Cardarelli M . Levels of vasopressin in children undergoing cardiopulmonary bypass. Cardiol Young. 2008; 18(2):135-40. DOI: 10.1017/S1047951108001881. View

10.

Novella S, Martinez A, Pagan R, Hernandez M, Garcia-Sacristan A, Gonzalez-Pinto A . Plasma levels and vascular effects of vasopressin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg. 2007; 32(1):69-76. DOI: 10.1016/j.ejcts.2007.03.047. View

11.

Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M . Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J. 2014; 78(9):2240-9. DOI: 10.1253/circj.cj-14-0244. View

12.

Rai T, Sekine K, Kanno K, Hata K, Miura M, Mizushima A . Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol. 1997; 8(9):1357-62. DOI: 10.1681/ASN.V891357. View

13.

Matsuyama K, Koizumi N, Nishibe T, Iwasaki T, Iwahasi T, Toguchi K . Effects of short-term administration of tolvaptan after open heart surgery. Int J Cardiol. 2016; 220:192-5. DOI: 10.1016/j.ijcard.2016.06.156. View

14.

EDMUNDS Jr L . Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1998; 66(5 Suppl):S12-6; discussion S25-8. DOI: 10.1016/s0003-4975(98)00967-9. View

15.

Sasaki S, Ohmoto Y, Mori T, Iwata F, Muraguchi M . Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method. Clin Exp Nephrol. 2011; 16(3):406-10. DOI: 10.1007/s10157-011-0574-2. View

16.

Matsuzaki M, Hori M, Izumi T, Fukunami M . Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011; 25 Suppl 1:S33-45. DOI: 10.1007/s10557-011-6304-x. View

17.

Mitsui M, Kataoka A, Nara Y, Nagura F, Kawashima H, Hioki H . Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow and normal-flow severe aortic stenosis. Heart Vessels. 2019; 34(10):1684-1691. DOI: 10.1007/s00380-019-01411-3. View

18.

Nielsen S, Terris J, Andersen D, Ecelbarger C, Frokiaer J, Jonassen T . Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci U S A. 1997; 94(10):5450-5. PMC: 24699. DOI: 10.1073/pnas.94.10.5450. View

19.

Schrier R, Gross P, Gheorghiade M, Berl T, Verbalis J, Czerwiec F . Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355(20):2099-112. DOI: 10.1056/NEJMoa065181. View

20.

Udelson J, Orlandi C, Ouyang J, Krasa H, Zimmer C, Frivold G . Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52(19):1540-5. DOI: 10.1016/j.jacc.2008.08.013. View